Herrington J D, Figueroa J A
Department of Pharmacy, Scott & White Clinic, Temple, Texas, USA.
Pharmacotherapy. 1997 Jan-Feb;17(1):163-5.
Paclitaxel is an antineoplastic agent derived from the bark of the Pacific yew tree that has activity against many tumors including breast and ovarian carcinomas. In the past, its extravasation quality has been considered to be a local irritant; however, recent reports suggest that the agent may be a vesicant. A patient experienced a delayed vesicant reaction to a paclitaxel extravasation that resulted in severe necrosis. No acute symptoms were reported at the time of extravasation from the 24-hour peripheral paclitaxel infusion. However, on day 11 the patient complained of severe and progressive pain at the site of extravasation. The site was erythematous and had areas of central necrosis requiring debridement and closure by a plastic surgeon. Because paclitaxel possesses vesicant characteristics, health care professionals should be aware of its potential extravasation hazard. Prolonged peripheral infusions should be avoided or administered with extreme caution.
紫杉醇是一种从太平洋紫杉树皮中提取的抗肿瘤药物，对包括乳腺癌和卵巢癌在内的多种肿瘤具有活性。过去，其外渗性质被认为是一种局部刺激物；然而，最近的报告表明该药物可能是一种发泡剂。一名患者对紫杉醇外渗出现延迟性发泡剂反应，导致严重坏死。在进行24小时外周紫杉醇输注外渗时未报告急性症状。然而，在第11天，患者抱怨外渗部位出现严重且进行性疼痛。该部位出现红斑，并有中央坏死区域，需要整形外科医生进行清创和缝合。由于紫杉醇具有发泡剂特性，医护人员应意识到其潜在的外渗风险。应避免长时间外周输注或极其谨慎地进行输注。
